|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | World’s first spaceflight on-orbit demonstration of a flexible solar array system based on shape memory polymer composites显示文摘With a 10%reversible compressive strain in more than 10 deformation cycles,the shape memory polymer composites(SMPCs)could be used for deployable structure and releasing mechanism.In this paper,without traditional electro-explosive devices or motors/controllers,the deployable SMPC flexible solar array system(SMPC-FSAS)is studied,developed,ground-based tested,and finally on-orbit validated.The epoxy-based SMPC is used for the rolling-out variable-stiffness beams as a structural frame as well as an actuator for the flexible blanket solar array.The releasing mechanism is primarily made of the cyanate-based SMPC,which has a high locking stiffness to withstand 50 g gravitational acceleration and a large unlocking displacement of 10 mm.The systematical mechanical and thermal qualification tests of the SMPC-FSAS flight hardware were performed,including sinusoidal sweeping vibration,shocking,acceleration,thermal equilibrium,thermal vacuum cycling,and thermal cycling test.The locking function of the SMPC releasing mechanisms was in normal when launching aboard the SJ20 Geostationary Satellite on 27 Dec.,2019.The SMPC-FSAS flight hardware successfully unlocked and deployed on 5 Jan.,2020 on geostationary orbit.The triggering signal of limit switches returned to ground at the 139 s upon heating,which indicated the successful unlocking function of SMPC releasing mechanisms.A pair of epoxy-based SMPC rolled variable-stiffness tubes,which clapped the flexible blanket solar array,slowly deployed and finally approached an approximate 100%shape recovery ratio within 60 s upon heating.The study and on-orbit successful validation of the SMPC-FSAS flight hardware could accelerate the related study and associated productions to be used for the next-generation releasing mechanisms as well as space deployable structures,such as new releasing mechanisms with low-shocking,testability and reusability,and ultra-large space deployable solar arrays. | LAN Xin LIU LiWu ZHANG FengHua LIU ZhengXian WANG LinLin LI QiFeng PENG Fan HAO SiDa DAI WenXu WAN Xue TANG Yong WANG Mian HAO YanYan YANG Yang YANG Cheng LIU YanJu LENG JinSong | 2020 | Science China(Technological Sciences)2020，63，8： | 7 |
| 2 | The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients显示文摘Type 1 diabetes mellitus is heterogeneous in many facets. The patients suffered from type 1 diabetes present several levels of islet function as well as variable number and type of islet-specific autoantibodies. This study was to investigate prevalence and heterogeneity of the islet autoantibodies and clinical phenotypes of type 1 diabetes mellitus; and also discussed the process of islet failure and its risk factors in Chinese type 1 diabetic patients. A total of 1,291 type 1 diabetic patients were enrolled in this study. Demographic information was collected. Laboratory tests including mixed-meal tolerance test, human leukocyte antigen alleles, hemoglobin A1 c, lipids, thyroid function and islet autoantibodies were conducted. The frequency of islet-specific autoantibody in newly diagnosed T1 DM patients(duration shorter than half year) was 73% in East China. According to binary logistic regressions, autoantibody positivity, longer duration and lower Body Mass Index were the risk factors of islet failure. As the disease developed, autoantibodies against glutamic acid decarboxylase declined as well as the other two autoantibodies against zinc transporter 8 and islet antigen 2. The decrease of autoantibodies was positively correlated with aggressive beta cell destruction. Autoantibodies can facilitate the identification of classic T1 DM from other subtypes and predict the progression of islet failure. As there were obvious heterogeneity in autoantibodies and clinical manifestation in different phenotypes of the disease, we should take more factors into consideration when identifying type 1 diabetes mellitus. | Jin Liu Lingling Bian Li Ji Yang Chen Heng Chen Yong Gu Bingqin Ma Wei Gu Xinyu Xu Yun Shi Jian Wang Dalong Zhu Zilin Sun Jianhua Ma Hui Jin Xing Shi Heng Miao Bing Xin Yan Zhu Zhenwen Zhang Ruifang Bu Lan Xu Guangde Shi Wei Tang Wei Li Dongmei Zhou Jun Liang Xingbo Cheng Bimin Shi Jixiang Dong Ji Hu Chen Fang Shao Zhong Weinan Yu Weiping Lu Chenguang Wu Li Qian Jiancheng Yu Jialin Gao Xiaoqiang Fei Qingqing Zhang Xueqin Wang Shiwei Cui Jinluo Cheng Ning Xu Guofeng Wang Guoqing Han Chunrong Xu Yun Xie Minmin An Wei Zhang Zhixiao Wang Yun Cai Qi Fu Yu Fu Shuai Zheng Fan Yang Qingfang Hu Hao Dai Yu Jin Zheng Zhang Kuanfeng Xu Yifan Li Jie Shen Hongwen Zhou Wei He Xuqin Zheng Xiao Han Liping Yu Jinxiong She Mei Zhang Tao Yang | 2016 | Science China(Life Sciences)2016，59，9： | 5 |
| 3 | Enhanced radioimmunotherapeutic efficacy of a monoclonal antibody cocktail against SMMC-7721 human hepatocellular carcinoma显示文摘The improved tumoricidal effect of the radioatibody mixture ('cocktail') has been reported recently for the treatment of colon tumor. In the present study, we demonstrated the enhanced radioimmunotherapeutic efficacy of a monoclonal atibody (MAb) cocktail against human hepatocellular carcinoma. Therapeutic efficacy was determined by measuring the change in tumor size over a period, determining the percentage of growth inhibition of each treatment at various times after radioantibody therapy. boioimmunotherapy of SMMC-7721 human hepatoma xenografts in athymic nude mice with combination of 131I labeled Hepama-1 and 131Llabeled 9403 mouse MAbs was more effective than using either Hepeam-1 or 9403 Mab alone The MAb cocktail could target a greater number of hepstoma cells and increase the magnitude of hepatoma cen uptde of radioamibodies. The in vjtro results explain the enhanced effect of the MAb cocktail in in vjvo model system. | SONG YI QIANG GEN FENG WANG XIN LAN DAI HONG XIE(Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Shanghai 200031, China) | 1998 | Cell Research1998，8，3： | 2 |
| 4 | Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome显示文摘Severe fever with thrombocytopenia syndrome(SFTS)virus(SFTSV)is an emerging tick-borne virus with high fatality and an expanding endemic.Currently,effective anti-SFTSV intervention remains unavailable.Favipiravir(T-705)was recently reported to show in vitro and in animal model antiviral efficacy against SFTSV.Here,we conducted a single-blind,randomized controlled trial to assess the efficacy and safety of T-705 in treating SFTS(Chinese Clinical Trial Registry website,number ChiCTR1900023350).From May to August 2018,laboratory-confirmed SFTS patients were recruited from a designated hospital and randomly assigned to receive oral T-705 in combination with supportive care or supportive care only.Fatal outcome occurred in 9.5%(7/74)of T-705 treated patients and 18.3%(13/71)of controls(odds ratio,0.466,95%Cl,0.174-1.247).Cox regression showed a significant reduction in case fatality rate(CFR)with an adjusted hazard ratio of 0.366(95%Cl,0.142-0.944).Among the low-viral load subgroup(RT-PCR cycle threshold>26),T-705 treatment significantly reduced CFR from 11.5 to 1.6%(P=0.029),while no between-arm difference was observed in the high-viral load subgroup(RT-PCR cycle threshold<26).The T-705-treated group showed shorter viral clearance,lower incidence of hemorrhagic signs,and faster recovery of laboratory abnormities compared with the controls.The in vitro and animal experiments demonstrated that the antiviral efficacies of T-705 were proportionally induced by SFTSV mutation rates,particularly from two transition mutation types.The mutation analyses on T-705-treated serum samples disclosed a partially consistent mutagenesis pattern as those of the in vitro or animal experiments in reducing the SFTSV viral loads,further supporting the anti-SFTSV effect of T-705,especially for the low-viral loads. | Hao Li Xia-Ming Jiang Ning Cui Chun Yuan Shao-Fei Zhang Qing-Bin Lu Zhen-Dong Yang Qin-Lin Xin Ya-Bin Song Xiao-Ai Zhang Hai-Zhou Liu Juan Du Xue-Juan Fan Lan Yuan Yi-Mei Yuan Zhen Wang Juan Wang Lan Zhang Dong-Na Zhang Zhi-Bo Wang Ke Dai Jie-Ying Bai Zhao-Nian Hao Hang Fan Li-Qun Fang Gengfu Xiao Yang Yang Ke Peng Hong-Quan Wang Jian-Xiong Li Lei-Ke Zhang Wei Liu | 2021 | Signal Transduction and Targeted Therapy2021，6，5： | 0 |
| 5 | Measurement of Br(n,γ)cross sections up to stellar s-process temperatures at the CSNS Back‑n显示文摘The neutron capture cross sections(n,γ)of bromine were obtained using the time-of-flight technique at the Back-n facility of the China Spallation Neutron Source.Promptγ-rays originating from neutron-induced capture events were detected using four C_(6)D_(6) detectors.The pulse-height weighting technique and double-bunch unfolding method based on Bayesian theory were used in the data analysis.Background deductions,normalization,and corrections were carefully considered to obtain reliable measurement results.The multilevel R-matrix Bayesian code SAMMY was used to extract the resonance parameters in the resolved resonance region(RRR).The average cross sections in the unresolved resonance region(URR)were obtained from 10 to 400 keV.The experimental results were compared with data from several evaluated libraries and previous experi-ments in the RRR and URR.The TALYS code was used to describe the average cross sections in the URR.The astrophysical Maxwell average cross sections(MACSs)of ^(79,81)Br from kT=5 to 100 keV were calculated over a sufficiently wide range of neutron energies.At a thermal energy of kT=30 keV,the MACS value for ^(79)Br 682±68 mb was in good agreement with the KADoNiS v1.0 recommended value.By contrast,the value of 293±29 mb for ^(81)Br was substantially higher than that of the evaluated database and the KADoNiS v1.0 recommended value. | Gao‑Le Yang Zhen‑Dong An Wei Jiang Xian‑Kai Li Wei‑Wei Qiu Zheng‑Fa Liao Zi‑Yue Zhuang Xiao‑Ping Zhang Sheng‑Li Chen Chen‑Chen Guo Er‑Xi Xiao Xiao Fang Xin‑Xiang Li Xin‑Rong Hu Bing Jiang Jin‑Cheng Wang Jie Ren Wen Luo Zhi‑Chao Zhu Hao‑Yang Lan Zong‑Wei Cao Xu Ma Ying‑Du Liu Pu‑Sen Wang Yi Yang Ping Su Xian‑Gai Deng Wan‑Bing He Chun‑Wang Ma Yu‑Ting Wang Zhi‑Tao Dai Peng‑Qin He Ren‑Guang Tang Tao Zhou Jing Wang Han Yi Yue Zhang Yong‑Hao Chen Rui‑Rui Fan Ke‑Qing Gao Qiang Li Kang Sun Zhi‑Xin Tan Min‑Hao Gu Han‑Tao Jing Jing‑Yu Tang | 2023 | Nuclear Science and Techniques2023，34，11： | 0 |
| 6 | 评估帕博利珠单抗在中国晚期黑色素瘤患者中的应用:基于KEYNOTE-151研究的3年随访数据显示文摘中国肢端和黏膜黑色素瘤的发病率较高,但治疗选择有限,晚期黑色素瘤患者的生存率普遍较低。对Ib期KEYNOTE-151研究的初步分析显示,帕博利珠单抗在作为二线药物治疗中国晚期黑色素瘤患者中,表现出了良好的耐受性和优异的临床抗肿瘤活性。本研究分析了3年随访的研究数据,纳入一线治疗后进展的不可切除的III/IV期中国黑色素瘤患者,给予帕博利珠单抗2 mg/kg治疗,每3周1次,最长使用35剂。主要终点为安全性和客观缓解率(objective response rate,ORR);次要终点包括疗效维持时间(duration of response,DOR)、无进展生存期(progression-free survival,PFS)和总生存期(overall survival,OS)。根据RECIST v1.1标准,采用独立中心盲法评估患者疗效。此外,根据黑色素瘤亚型,以及BRAF突变状态和PD-L1表达状态(仅肢端黑色素瘤)进行亚组分析。本研究共纳入103例患者,中位随访时间[从首次用药到数据截止时间(2020年7月13日)]为44.6个月[四分位距(interquartile range,IQR):39.1–46.2]。85.4%的患者发生了任一级别的治疗相关不良事件(treatment-related adverse events,TRAEs),12.6%的患者发生了3/4级的TRAEs,无5级TRAE发生。3例患者因TRAEs(免疫相关肝炎、肺炎和关节炎)停药。免疫相关AEs和输液反应发生比例为34.0%(3/4级,2.9%)。ORR为17.6%(95%CI:10.8–26.4;1例完全缓解/17例部分缓解),中位DOR为13.8个月(范围:2.7–37.4+)。中位PFS为2.8个月(95%CI:2.7–3.5),36个月的PFS率为5.0%。中位OS为13.2个月(95%CI:10.4–16.5),36个月的OS率为22.3%。肢端黑色素瘤中位OS为14.8个月,非肢端皮肤黑色素瘤为13.5个月,黏膜黑色素瘤为7.4个月。在肢端黑色素瘤亚组中,程序性死亡配体-1(programmed death ligand-1,PD-L1)阳性的中位OS为22.8个月,PD-L1阴性的中位OS为8.4个月,BRAF野生型的中位OS为18.5个月,BRAF突变型的中位OS为5.8个月。综上,本研究对3年随访数据分析结果表明,帕博利珠单抗作为二线治疗在中国晚期黑色素瘤患者中的安全性可控,且达到了具有临床意义的抗肿瘤活性,使部分患者获得持久缓解。亚组分析表明PD-L1阳性和BRAF野生型的肢端黑色素瘤患者从该治疗中获益较大,但由于亚组样本量较小,该研究结论仍需进一步验证。 | Lu Si Xiaoshi Zhang Yongqian Shu Hongming Pan Di Wu Jiwei Liu Lili Mao Xuan Wang Xizhi Wen Yanhong Gu Lingjun Zhu Shijie Lan Xin Cai Scott J.Diede Haiyan Dai Cuizhen Niu Jianfeng Li Jun Guo 李雯钰(翻译校对) 斯璐(点评) | 2023 | 癌症2023，42，8： | 0 |
| 7 | A Shape-Memory Deployable Subsystem with a Large Folding Ratio in China’s Tianwen-1 Mars Exploration Mission显示文摘Once China’s Tianwen-1 Mars probe arrived in a Mars orbit after a seven-month flight in the deep cold space environment,it would be urgently necessary to monitor its state and the surrounding environment.To address this issue,we developed a flexible deployable subsystem based on shape memory polymer composites(SMPC-FDS)with a large folding ratio,which incorporates a camera and two temperature telemetry points for monitoring the local state of the Mars orbiter and the deep space environment.Here,we report on the development,testing,and successful application of the SMPC-FDS.Before reaching its Mars remote-sensing orbit,the SMPC-FDS is designed to be in a folded state with high stiffness;after reaching orbit,it is in a deployed state with a large envelope.The transition from the folded state to the deployed state is achieved by electrically heating the shape memory polymer composites(SMPCs);during this process,the camera on the SMPC-FDS can capture the local state of the orbiter from multiple angles.Moreover,temperature telemetry points on the SMPC-FDS provide feedback on the environment temperature and the temperature change of the SMPCs during the energization process.By simulating a Mars on-orbit space environment,the engineering reliability of the SMPC-FDS was comprehensively verified in terms of the material properties,structural dynamic performance,and thermal vacuum deployment feasibility.Since the launch of Tianwen-1 on 23 July 2020,scientific data on the temperature environment around Tianwen-1 has been successfully acquired from the telemetry points on the SMPCFDS,and the local state of the orbiter has been photographed in orbit,showing the national flag of China fixed on the orbiter. | Chengjun Zeng Liwu Liu Yang Du Miao Yu Xiaozhou Xin Tianzhen Liu Peilei Xu Yu Yan Dou Zhang Wenxu Dai Xin Lan Fenghua Zhang Linlin Wang Xue Wan Wenfeng Bian Yanju Liu Jinsong Leng | 2023 | Engineering2023，，9： | 0 |
| 8 | Differential regulation of JAK1 expression by ETS1 associated with predisposition to primary biliary cholangitis显示文摘Primary biliary cholangitis(PBC)is an autoimmune liver disease characterized by the destruction of intrahepatic small bile ducts and progressive cholestasis,eventually leading to liver cirrhosis and hepatic failure without appropriate treatment(Terziroli Beretta-Piccoli et al.,2019). | Peng Jiang Chan Wang Mingming Zhang Ye Tian Weifeng Zhao Junyi Xin Yexi Huang Zhibin Zhao Wenjuan Sun Jie Long Ruqi Tang Fang Qiu Xingjuan Shi Yi Zhao Li Zhu Na Dai Lei Liu Xudong Wu Jinshan Nie Bo Jiang Youlin Shao Yueqiu Gao Jianjiang Yu Zhigang Hu Zhidong Zang Yuhua Gong Yaping Dai Lan Wang Ningling Ding Ping Xu Sufang Chen Lu Wang Jing Xu Luyao Zhang Junyan Hong Ruonan Qian Hu Li Xuan Jiang Congwei Chen Wenyan Tian Jian Wu Yuzhang Jiang Chongxu Han Kui Zhang Hong Qiu Li Li Hong Fan Liming Chen Jianqiong Zhang Zhongsheng Sun Xiao Han Zhenhua Dai Erguang Li M.Eric Gershwin Zhexiong Lian Xiong Ma Michael F.Seldin Weichang Chen Meilin Wang Xiangdong Liu | 2023 | Journal of Genetics and Genomics2023，50，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员